Policy and Advocacy
HTA & Access to Innovative Oncology Drugs | Event at the European Parliament
In light of the European Commission legislative proposal for future EU cooperation on Health Technology Assessment, the European Cancer Patient Coalition and the Cancer Drug Development Forum will host a high-level discussion together with Elisabetta Gardini MEP. It will bring together stakeholders and policymakers to highlight the importance of a more harmonised approach to Health Technology Assessment for ensuring timely access to innovative oncology diagnostics and treatments.
Very few HTA agencies in Europe involve patients in their assessments and, where public engagement is sought, the approaches vary. Therefore, even though the European Commission proposal seeks to establish methods for providing patient evidence, more robust patient engagement schemes are needed at both the EU and Member State levels.
DETAILED AGENDA TBC
This session is part of a 2-day Multi-Stakeholder Workshop on Biomarkers and Patients’ Access to Personalized Oncology Drugs in Europe organised by the Cancer Drug Development Forum in collaboration with ECPC. The workshop will take place at the Thon Hotel EU in Rue de la Loi 75, Brussels and will host experts coming from academia, industry, and patients representative.